Imaging of triple-negative breast cancer

Annals of Oncology

Volumn 23, Issue SUPPL. 6, 2012, Pages

  Dogan, B E ^a   Turnbull, L W ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

18F FDG PET; Breast MRI; Breast ultrasound; Mammography; Neoadjuvant chemotherapy; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18;

ARTICLE; AXILLARY LYMPH NODE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; ECHOMAMMOGRAPHY; HIGH RISK PATIENT; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

EID: 84867137030     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds191     Document Type: Article

References (38)

1. Kim MJ, Ro JY, Ahn SH et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neuoverexpressing phenotypes. Hum Pathol 2006; 37: 1217-1226.
2. Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 2007; 9: R4.
3. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
4. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.
5. Lin NU, Vanderplas A, Hughes ME et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). J Clin Oncol 2009; 27: 15s: Abstr 543.
6. Dolle JM, Daling JR, White E et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009; 18: 1157-1166.
7. Millikan R, Newman B, Tse C-K et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123.
8. Yang WT, Dryden M, Broglio K et al. Mammographic features of triple receptornegative primary breast cancers in young premenopausal women. Breast Cancer Res Treat 2008; 111: 405-410.
9. Wang Y, Ikeda DM, Narasimhan B et al. Estrogen receptor-negative invasive breast cancer: imaging features of tumors with and without human epidermal growth factor receptor type 2 overexpression. Radiology 2008; 246: 367-375.
10. Dogan BE, Gonzalez-Angulo AM, Gilcrease M et al. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. Am J Roentgenol 2010; 194: 1160-1166.
11. Ko ES, Lee BH, Kim HA et al. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol 2010; 20: 1111-1117.
12. Kojima Y, Tsunoda H. Mammography and ultrasound features of triple-negative breast cancer. Breast Cancer 2010; 18: 146-151.
13. American College of Radiology (ACR). ACR BI-RADS®: mammography, 4th edition. In ACR Breast Imaging Reporting and Data System, Breast Imaging Atlas. Reston, VA. American College of Radiology 2003.
14. Lerma E, Peiro G, Ramón T et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). Mod Pathol 2007; 20: 1200-1207.
15. Tsuda H, Takarabe T, Hasegawa T et al. Myoepithelial differentiation in highgrade invasive ductal carcinomas with large central acellular zones. Hum Pathol 1999; 30: 1134-1139.
16. Fulford L, Easton D, Reis-Filho J et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinomas of breast. Histopathology 2006; 49: 22-34.
17. Chen JH, Agrawal G, Feig B et al. Triple-negative breast cancer: MRI features in 29 patients. Ann Oncol 2007; 18: 2042-2043.
18. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657.
19. Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR findings and pathological findings. Radiology 2009; 250: 638-647.
20. Li SP, Padhani AR, Taylor J et al. Vascular characterisation of triple negative breast carcinomas using dynamic MRI. Eur Radiol 2011; 21: 1364-1373.
21. Groheux D, Giacchetti S, Moretti JL et al. Correlation of high 18F-FDG uptake to clinical, pathological, and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 2010; 38: 426-435.
22. Schwarz-Dose J, Untch M, Tiling R et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009; 27: 535-541.
23. Basu S, Chen W, Tchou J et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters. Cancer 2008; 112: 995-1000.
24. Yang WT, Ahuja A, Tang A et al. High resolution sonographic detection of axillary lymph node metastases in breast cancer. J Ultrasound Med 1996; 15: 241-246.
25. Straver ME, Aukema TS, Olmos RA et al. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imaging 2010; 37: 1069-1076.
26. MARIBS Study Group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multi-centre cohort study (MARIBS). Lancet 2005; 365: 1769-1778.
27. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2007; 11: 5678-5682.
28. Turnbull LW, Brown SR, Olivier C et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess 2010; 14: 1-182.
29. Padhani AR, Hayes C, Assersohn L et al. Prediction of clinicopathological response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: Initial clinical results. Radiology 2006; 239: 361-374.
30. Buccholz TA, Lehman CD, Harris JR et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute Conference. J Clin Oncol 2008; 26: 791-797.
31. Chen JH, Feig B, Agrawal G et al. MRI evaluation of pathologically complete response and residual tumours in breast cancer after neoadjuvant chemotherapy. Cancer 2008; 112: 17-26.
32. Loo CE, Straver ME, Rodenhuis S et al. Magnetic resonance response monitoring of breast cancer during neoadjuvant chemotherapy: Relevance of breast cancer subtypes. J Clin Oncol 2011; 29: 660-666.
33. Moon H-G, Han W, Lee JW et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumour extent after neoadjuvant systemic therapy. Ann Oncol 2009; 20: 636-641.
34. Theilmann RJ, Borders R, Trouard TP et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia 2004; 6: 831-837.
35. Fuster D, Duch J, Paredes P et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008; 26: 4746-4751.
36. Martoni AA, Zamagni C, Quercia S et al. Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer 2010; 116: 805-813.
37. McDermott GM, Welch A, Staff RT et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 2007; 102: 75-84.
38. Tchou J, Sonnad SS, Bergey MR et al. Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol 2010; 12: 657-662.